Citalopram for Depression
Citalopram hydrobromide (Celexa - Forest/Parke-Davis), a selective serotonin reuptake inhibitor (SSRI) available in Europe since 1989, has now been approved by the US Food and Drug Administration (FDA) for treatment of depression. It is being advertised as having a 'favorable side-effect profile.'...
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Citalopram for Depression
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1041
Article Code: 1041a
Date: December 4, 1998
Volume: 40
Pages: 113-114
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1041
Article Code: 1041a
Date: December 4, 1998
Volume: 40
Pages: 113-114
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)